CD19 and B-cell non-Hodgkin lymphoma: In 2020, Fate Therapeutics Inc. announced that its anti-CD19 CAR-NK cells showed stronger cytotoxicity against CD20+ lymphoma cells in patients with r/r B cell lymphoma (BCL) when combined with the CD20 antibody–drug rituximab.